All trading involves risk. Contracts for Difference (CFDs) are complex instruments and may not be suitable for all investors. Please refer to Risk Disclosure and Risk Fact Sheet on Capital.com/en-sg.
Open platformOpen platform

BeyondSpring Presents Plans for 442-Patient Phase 3 Plinabulin Trial in Lung Cancer

By Public Technologies
  • BeyondSpring plans to start its 442-patient DUBLIN-4 confirmatory Phase 3 trial of plinabulin in 2026-2027.
  • The study will compare plinabulin plus docetaxel against docetaxel in post-immunotherapy, driver-negative, non-squamous non-small cell lung cancer.
  • Overall survival is the primary endpoint; an interim analysis is expected in 2028 following 221 progression-free survival events.
  • DUBLIN-4 has FDA Fast Track designation, with enrollment planned evenly between China and Western regions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief on November 13, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.